Clinical Research Directory
Browse clinical research sites, groups, and studies.
⁶⁸Ga-DPA in the Lung Cancer Diagnosis
Sponsor: Peking Union Medical College Hospital
Summary
In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile and excellent imaging performance. Leveraging the established strengths of the Department of Nuclear Medicine at Peking Union Medical College Hospital, we now plan to conduct an exploratory PET/CT imaging study in lung cancer patients. This study aims to provide an in vivo, non-invasive, and visualizable technique for detecting PD-L1 expression levels and spatial distribution in tumors. It will further validate the clinical utility of this technology, offering critical diagnostic insights for initial assessment and treatment efficacy evaluation in PD-L1-positive tumor patients undergoing PD-L1-targeted therapies.
Official title: Clinical Application of PD-L1 Targeted Imaging Agent ⁶⁸Ga-DPA in the Diagnosis of Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-09-28
Completion Date
2027-09-28
Last Updated
2025-06-15
Healthy Volunteers
No
Conditions
Interventions
68Ga-DPA PET/CT
Use 68Ga-DPA PET/CT in the diagnosis of lung cancer
Locations (1)
100730
Beijing, China